Nyaku, A. N., Zheng, L., Gulick, R. M., Olefsky, M., Berzins, B., Wallis, C. L., . . . Taiwo, B. O. (2019). Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: Week 48 outcomes from ACTG 5353. J Antimicrob Chemother.
Citação norma ChicagoNyaku, Amesika N., et al. "Dolutegravir Plus Lamivudine for Initial Treatment of HIV-1-infected Participants With HIV-1 RNA <500 000 Copies/mL: Week 48 Outcomes From ACTG 5353." J Antimicrob Chemother 2019.
Citação norma MLANyaku, Amesika N., et al. "Dolutegravir Plus Lamivudine for Initial Treatment of HIV-1-infected Participants With HIV-1 RNA <500 000 Copies/mL: Week 48 Outcomes From ACTG 5353." J Antimicrob Chemother 2019.
Nota: a formatação da citação pode não corresponder 100% ao definido pela respectiva norma.